Interview with Doru Torge, General Manager, Ferring Pharmaceuticals SA…
Ferring is a company with a tremendous history dating back to the 1950s in Sweden. Now present in over 50 countries, the Group has managed to maintain a double digit…
Address: Coriolan Brediceanu Str., no 10 City Business Center B Building, 1st Floor, Timisoara, Romania
Tel: +40 35 611 32 70
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 50 countries and employ more than 4000 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, USA, Israel, India and China.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
For fifty years, we have been at the forefront of innovation in the field of naturally occurring human peptides. We have developed treatments in areas that span the human life cycle, including: reproductive health, endocrinology, gastroenterology and urology:
Ferring’s infertility treatments give infertile couples the chance to have babies
In obstetrics, Ferring helps premature children to be born healthy and without handicaps
With treatments in endocrinology, Ferring gives children the chance to overcome growth deficiencies
Ferring’s inflammatory bowel disease (IBD) treatments enable young adults with IBD to live a normal life
In urology, Ferring’s treatment for nocturia and bedwetting helps adults and children to an undisturbed night’s sleep
Ferring’s testosterone replacement treatment improves the key symptoms of low testosterone, reduces fat and improves muscle strength and mood
Ferring’s hormonal therapy for prostate cancer offers a new treatment option to men with an advanced hormone-dependent cancer
Ferring’s strength is our extensive knowledge of peptides and the role they play in the human body.
Ferring is a company with a tremendous history dating back to the 1950s in Sweden. Now present in over 50 countries, the Group has managed to maintain a double digit…
Norina Alinta Gavan, CEO of Wörwag Pharma Romania, reveals how the affiliate will become more active and entrepreneurial with the change in shareholding while having an increased responsibility for the…
Simona Cocos of Zentiva Romania explains how the affiliate has developed since its separation from Sanofi and how recent acquisitions have impacted local operations. She shares how the extremely diversified…
Pascal Robin, country chair of Sanofi and general manager of Sanofi Pasteur for Romania and Moldova, shares his insights on the intrinsic and extrinsic factors that helped Sanofi become a…
Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a state-of-art stem cell therapy. She highlights the…
Iulia Arif-Percă executive director of the Local American Working Group (LAWG), shares her insights on the launched initiatives to finding new funding alternatives that will increase Romanian patients’ access to…
Dan Zaharescu, executive director of the Romanian Association of Pharmaceutical Manufacturers (ARPIM), shares his insights on market access, the need to reform pricing methodologies, the debate around the claw-back tax,…
László Attila, president of the Committee of Public Health of Romania, highlights the Committee’s efforts to mitigate the detrimental effects of Romania’s looming demographic crisis and medical “brain-drain”. Furthermore, he…
Valentina Băicuianu and Adrian Grecu of the APMGR, share their insights on the deteriorating environment for generics in Romania, with unfavourable pricing methodology and a rising and an unpredictable clawback…
Schalk Opperman, general manager of Merck Romania explains the key factors behind successful product launches in what is an unpredictable market. He shares his insights on Merck’s impressive growth in…
State hospitals in Bucharest are increasingly overloaded with patients due to a lack of resources and specialists. This pressure is amplified by the fact that many Romanians turn to emergency…
The Romanian Association of the Self-Care Industry (RASCI) was established in 2016 as the “voice” of the Romanian consumer healthcare industry. Diana Mereu, CEO of RASCI, discusses the association’s mission,…
As anti-vaccination sentiments resurface globally, so have once-eradicated diseases. This situation is especially prevalent in Romania and has become a severe economic, social, and health threat. Romania’s Struggle with…
See our Cookie Privacy Policy Here